Brought to you by 
Vical, Vascular Genetics, HGS end gene drug deal
17 Apr 2007
Executive Summary
Human Genome Sciences (gene- and protein-based drugs), Vascular Genetics (gene therapy products for vascular disease), and Vical (gene-based vaccines), will develop genes as pharmaceuticals to prevent and treat various diseases. The collaboration will use Vical's naked DNA delivery technology, genes in HGS' database, and products in development at Vascular Genetics.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vical, Vascular Genetics, HGS end gene drug deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice